ArticleArchives of gynecology and obstetrics2025
Value of serum uric acid in a risk prediction model for postmenopausal osteoporosis.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Routine Laboratory Markers as Incremental Predictors Beyond OSTA for Dual-Energy X-Ray Absorptiometry-Defined Osteoporosis: Internal Validation in a Referral Cohort.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential role of serum uric acid (UA) in risk stratification for postmenopausal osteoporosis (PMOP) and to establish an accessible risk prediction model that can aid in early screening and diagnosis.
methodsWe retrospectively enrolled 295 postmenopausal women who underwent dual-energy X-ray absorptiometry (DXA) at Zhuhai Hospital affiliated with Jinan University from July 2021 to July 2023. Participants were divided into a PMOP group (T-score < -2.5; n = 125) and a control group (T-score ≥ -2.5; n = 170). Clinical and laboratory data were collected, including markers of inflammation, renal function, and uric acid levels. Univariable and multivariable logistic regression analyses identified independent risk factors for PMOP. A nomogram was constructed based on the final logistic regression model and evaluated for discrimination and calibration using receiver operating characteristic (ROC) curves, calibration curves, and the concordance index (C-index).
resultsThe PMOP group exhibited significantly higher mean values of age, alkaline phosphatase (ALP), neutrophil count (NEU), monocyte count (MO), monocyte-to-lymphocyte ratio (MLR), and the systemic immune-inflammation index (SII), while demonstrating significantly lower lymphocyte counts (LYM), height, OSTA scores, and albumin (ALB). Serum UA values were slightly lower in the PMOP group than in the control group. Multivariable logistic regression yielded a prediction model incorporating ALB, ALP, MLR, and UA. The area under the ROC curve (AUC) for this model was 0.781 (95% CI: 0.682-0.879). The calibration curve aligned well with the ideal reference line, and the C-index was 0.779 (95% CI: 0.728-0.831).
conclusionSerum uric acid may have a contributory role in risk stratification for PMOP when combined with key clinical and laboratory markers. This nomogram-based model demonstrates moderate predictive performance; future large-scale multicenter prospective cohorts are warranted to validate these findings and to refine the model by accounting for potential confounding factors such as medication use, dietary intake, and lifestyle habits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.